Role of metastasis-directed treatment in kidney cancer

Area of Science:

• Oncology
• Urology

Background:

• Novel systemic agents for metastatic renal cell carcinoma (mRCC) have advanced treatment, but durable complete responses remain rare.
• Definitive treatment of metastatic sites is crucial for local control, symptom palliation, and potentially curative outcomes in mRCC.

Purpose of the Study:

• To review the evidence supporting definitive local treatments for metastatic renal cell carcinoma (mRCC).
• To discuss multimodal treatment approaches combining local therapies with systemic agents.
• To outline patient selection criteria and risk-stratification tools for guiding treatment decisions.

Main Methods:

• Review of existing evidence on definitive treatment modalities for mRCC.
• Examination of surgical metastasectomy, thermal ablation, and radiotherapy.
• Discussion of minimally invasive options and multimodal strategies.

Main Results:

• Definitive local treatment is a cornerstone of mRCC management, offering potential for cure.
• Surgical metastasectomy, thermal ablation, and radiotherapy are key local treatment options.
• Multimodal approaches, including combining surgery with systemic agents, are increasingly important.

Conclusions:

• Local therapies remain vital for managing metastatic renal cell carcinoma (mRCC), offering the only potentially curative option.
• Patient selection and risk stratification are essential for optimizing outcomes with definitive mRCC treatment.
• Combining local treatments with novel systemic therapies represents a promising strategy for improving mRCC management.